Brought to you by 
Opsona brings in €18mm through its Series B round
27 Feb 2009
Executive Summary
Opsona Therapeutics (treatments for autoimmune diseases and inflammation) raised €18mm ($23mm) through its Series B round. New and existing investors participated, including Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital, and Seroba Kernal Life Sciences. Novartis Venture Fund and Fountain Healthcare executives took seats on the company's board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Opsona brings in €18mm through its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice